RAVI D RAO MD NPI 1417927054

NPI Details

Ravi D Rao, MD is a hematology and oncology internal medicine in Fresno, CA with 29 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Ravi D Rao, MD NPI is 1417927054. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

7130 N MILLBROOK AVE
FRESNO, CA
ZIP 93720-347
Phone: (559) 326-1222
Fax: (559) 326-1225

The NPI 1417927054 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml (HCPCS:Q9967)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, granisetron, extended-release, 0.1 mg (HCPCS:J1627)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, rituximab-arrx, biosimilar, (riabni), 10 mg (HCPCS:Q5123)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Electrophoresis, laboratory testing technique (HCPCS:82664)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Nuclear medicine study from skull base to mid-thigh with ct scan (HCPCS:78815)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Thyroid hormone, t3 measurement, free (HCPCS:84481)
• Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries (HCPCS:A9552)
• Red blood count, automated test (HCPCS:85045)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Unclassified drugs (HCPCS:J3490)
• Urinalysis, manual test (HCPCS:81002)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Red blood cell sedimentation rate, to detect inflammation, non-automated (HCPCS:85651)
• Follow-up hospital inpatient care per day, typically 35 minutes (HCPCS:99233)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Thyroxine (thyroid chemical), total (HCPCS:84436)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Ct scan of abdomen and pelvis with contrast (HCPCS:74177)
• Piflufolastat f-18, diagnostic, 1 millicurie (HCPCS:A9595)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Blood test, clotting time (HCPCS:85610)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• Thyroxine (thyroid chemical), free (HCPCS:84439)
• Folic acid level, serum (HCPCS:82746)
• Blood test, basic group of blood chemicals (calcium, total) (HCPCS:80048)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 (HCPCS:86301)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Ct scan of chest with contrast (HCPCS:71260)
• Haptoglobin (serum protein) level (HCPCS:83010)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection, alteplase recombinant, 1 mg (HCPCS:J2997)
• Uric acid level, blood (HCPCS:84550)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Coagulation assessment blood test, plasma or whole blood (HCPCS:85730)
• Vitamin d-3 level (HCPCS:82306)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Declotting of central venous tube (HCPCS:36593)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Nuclear medicine study whole body with ct scan (HCPCS:78816)
• Drawing of blood for a medical problem (HCPCS:99195)
• Biopsy and aspiration of bone marrow sample for diagnosis (HCPCS:38222)
• Magnesium level (HCPCS:83735)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Ct scan of abdomen before and after contrast (HCPCS:74170)
• Ct scan of abdomen and pelvis without contrast (HCPCS:74176)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine split virus, preservative free (HCPCS:90662)
• Ct scan of chest without contrast (HCPCS:71250)
• Glutamyltransferase (liver enzyme) level (HCPCS:82977)

The enumeration date for this NPI number is 1/25/2006 and was last updated on 1/27/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.